CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer

MLA

M. G. Filippone, et al. “CDK12 Promotes Tumorigenesis but Induces Vulnerability to Therapies Inhibiting Folate One-Carbon Metabolism in Breast Cancer.” Nature Communications, vol. 13, no. 1, May 2022, pp. 1–19. EBSCOhost, https://doi.org/10.1038/s41467-022-30375-8.

APA

M. G. Filippone, D. Gaglio, R. Bonfanti, F. A. Tucci, E. Ceccacci, R. Pennisi, M. Bonanomi, G. Jodice, M. Tillhon, F. Montani, G. Bertalot, S. Freddi, M. Vecchi, A. Taglialatela, M. Romanenghi, F. Romeo, N. Bianco, E. Munzone, F. Sanguedolce, … S. Pece. (2022). CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer. Nature Communications, 13(1), 1–19. https://doi.org/10.1038/s41467-022-30375-8

Chicago

M. G. Filippone, D. Gaglio, R. Bonfanti, F. A. Tucci, E. Ceccacci, R. Pennisi, M. Bonanomi, et al. 2022. “CDK12 Promotes Tumorigenesis but Induces Vulnerability to Therapies Inhibiting Folate One-Carbon Metabolism in Breast Cancer.” Nature Communications 13 (1): 1–19. doi:10.1038/s41467-022-30375-8.